Medical weight loss with real medicine, real providers.

GLP-1 receptor agonists are prescription medications that mimic a hormone your gut releases after eating. They slow gastric emptying, reduce appetite, and help regulate blood sugar, which together make it easier to eat less without fighting constant hunger. Semaglutide and tirzepatide are the most well-studied examples, and they’re the two we prescribe. Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is a dual agonist, working on both GLP-1 and GIP receptors, which produces larger average weight loss in head-to-head trials. Both are once-weekly subcutaneous injections you give yourself at home, with the dose titrated monthly by your provider. These are real medications, not wellness products, which is why we prescribe them with an in-person evaluation, baseline labs, and ongoing monitoring rather than an online questionnaire.

In clinical trials, patients on semaglutide lost about 15% of their starting body weight on average over 68 weeks. Tirzepatide trials showed 18 to 22% at the highest dose. In our program we tell patients to plan on roughly 12 to 15% with semaglutide and 18 to 22% with tirzepatide, with the dose titrated monthly over four to six months on semaglutide and five to seven on tirzepatide. Individual results vary with dose, nutrition, activity, and how long you stay on therapy. The medication works on appetite and blood sugar. It does not build muscle, fix sleep, or repair a difficult relationship with food, so patients who treat it as a partner to their own effort get the best outcomes. We track body composition, not only the number on the scale.

Generally, adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition like prediabetes, hypertension, or sleep apnea. Type 2 diabetes or prediabetes, and prior weight-loss efforts that have plateaued, both point toward candidacy. Your provider reviews your full history, current medications, and baseline labs to make the final call, so the screening question and the clinical decision aren’t the same thing. There are firm exclusions as well: no personal or family history of medullary thyroid cancer or MEN2, and not pregnant or breastfeeding. Because this is an in-person program with monthly visits, you also need to be able to get to the Palm Harbor clinic for follow-up. Cosmetic weight loss at a normal BMI, without a medical indication, is not something we prescribe for.

Most side effects are gastrointestinal and dose-dependent: nausea, reflux, constipation, or feeling full earlier than usual. They tend to be most noticeable in the first weeks and after each dose step, and they usually improve as your body adapts. Slower titration is the main tool we use, along with hydration, protein-forward meals, and smaller portions eaten more slowly. If a dose step isn’t tolerated, we hold or step back instead of pushing through it, which is one of the practical advantages of monthly in-person visits over an automatic refill. Side-effect management is part of every check-in, not an afterthought. We also repeat labs around week twelve, checking A1c, lipids, kidney, and liver function, so tolerance and metabolic improvement are tracked together rather than guessed at.

Our GLP-1 program is self-pay. We price it transparently with no hidden fees, and most patients find it competitive with the out-of-pocket cost of brand-name GLP-1s after an insurance denial or a high copay. For context, brand-name Wegovy or Zepbound without coverage runs roughly $1,000 to $1,350 per month at the pharmacy counter. There are no membership fees, no renewal charges, and no extra consult fees between visits. The program price covers your personalized medication prepared by a licensed US pharmacy and delivered monthly, in-person visits with Dr. Oliver Morris, baseline and follow-up labs at scheduled checkpoints, titration, side-effect management, and nutrition guidance. We quote the full program cost at consultation so you can see the total for the expected treatment window instead of a teaser monthly number.

You see an actual provider in person, get real baseline labs, and get continuous care from the same clinician every month. Online services sell a prescription. We deliver a medical program. The practical differences: an async questionnaire versus an in-person consult, black-box dispensing versus a plan you can see, limited lab review versus a full baseline panel with follow-up labs, and rotating prescribers on chat support versus Dr. Oliver Morris at every visit. With most telehealth programs, if you stop messaging, the medication stops. Here, dose changes come from your weight trend, tolerance, body composition, and labs, reviewed face to face at our Palm Harbor clinic. Nutrition and body composition guidance are built into the visit, because the medication is one part of the plan rather than the whole plan.

GLP-1 therapy is typically a 12 to 18 month program, sometimes longer, with the goal of reaching a maintenance dose once you hit your target weight. The first four to six months are mostly titration. By weeks 16 to 24 most patients sit at a steady dose with stable side effects, and that’s where taper planning begins rather than at the end. Stopping abruptly often leads to weight regain, so coming off is done gradually and under supervision. What sets the timeline is your response, not a fixed calendar: weight trend, labs, tolerance, and how solid your nutrition, training, and sleep habits have become. Some patients hold a low maintenance dose long term. Others taper off completely. We make that call together at a clinical checkpoint.

Semaglutide and tirzepatide have extensive safety data from multi-year clinical trials in diabetes and obesity, which is more long-term evidence than most weight-loss interventions can point to. Most patients tolerate them well under supervision. That said, safe long-term use depends on the monitoring around the medication. We recheck labs at scheduled checkpoints, including A1c, lipids, kidney, and liver function, so we’re watching metabolic markers rather than only the scale. Monthly visits catch tolerance problems early, while a dose adjustment is still enough. There are also patients we won’t prescribe to at all, including anyone with a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, or severe gastroparesis. Long-term safety comes down to who gets prescribed the medication and how closely they’re followed.

GLP-1 medications are not prescribed for patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, during pregnancy or breastfeeding or when pregnancy is planned in the near term, with active pancreatitis or a history of pancreatic disease, or with severe gastroparesis or a significant gastrointestinal motility disorder. We also don’t prescribe for patients under 18, or over 75 without a clear clinical rationale and coordination with primary care, or for anyone with an active eating disorder that hasn’t been evaluated and stabilized. If your goal is cosmetic weight loss at a normal BMI without a medical indication, this isn’t the right program. The same is true if you want a cash-and-carry monthly supply with no labs, visits, or follow-up. We’d rather say so upfront than waste your consult.

We quote pricing at consultation because the right medication, dose, and duration depend on your labs and goals. There are no hidden membership fees and no renewal charges. The price includes your monthly visit with the provider, the medication prepared by a licensed US pharmacy and delivered each month, labs at scheduled checkpoints, titration, side-effect management, and nutrition guidance. For comparison, brand-name Wegovy or Zepbound without insurance coverage runs roughly $1,000 to $1,350 per month at the pharmacy counter, and telehealth GLP-1 programs range widely, often with bolt-on fees and rotating prescribers. Our program is priced to be competitive with the first and clinically stronger than the second. At the consult we give the full cost for the expected treatment window, not just a monthly figure that shifts as your dose changes.

Not necessarily. Many patients taper to a lower maintenance dose once they reach goal weight, and some stop entirely after building nutrition and lifestyle habits that hold on their own. The decision is made together at a clinical checkpoint, not by default and not because a subscription lapsed. What makes stopping realistic is what you built while on the medication: protein intake around one gram per pound of target body weight, resistance training on a regular schedule, and sleep that supports appetite regulation. Patients who never establish those tend to regain when the medication comes off, which is why taper planning starts around weeks 16 to 24 rather than at the finish line. If you come off and your weight drifts back, restarting at a maintenance dose is a reasonable option.